A conceptual model of psychoneurological symptom cluster variation in women with breast cancer: Bringing nursing research to personalized medicine

Current Pharmacogenomics and Personalized Medicine

Volumn 11, Issue 3, 2013, Pages 224-230

  Starkweather, Angela R ^a   Lyon, Debra E ^a   Elswick, R K ^a   Montpetit, Alison J ^a   Conley, Yvette ^b   McCain, Nancy L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Breast cancer; Epigenetics; Genetics; Hypothalamic pituitary adrenal axis; Personalized medicine; Psychoneuroimmunology; Psychoneurological symptoms; Symptom clusters

Indexed keywords

CHEMOKINE RECEPTOR CXCR5; CHOLINERGIC RECEPTOR; CORTICOTROPIN RECEPTOR; CORTICOTROPIN RELEASING FACTOR; CXCL2 CHEMOKINE; CYCLOOXYGENASE 2; GLUCOCORTICOID RECEPTOR; I KAPPA B KINASE BETA; INDOLEAMINE; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MATRIX METALLOPROTEINASE; MINERALOCORTICOID RECEPTOR; NORADRENALIN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA;

ANXIETY; ARTICLE; BREAST CANCER; CONCEPTUAL FRAMEWORK; DEPRESSION; DNA DAMAGE; EPIGENETICS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; NONHUMAN; NURSING RESEARCH; OXIDATIVE STRESS; PERCEIVED STRESS SCALE; PERSONALIZED MEDICINE; PSYCHOANALYSIS; QUALITY OF LIFE; SINGLE NUCLEOTIDE POLYMORPHISM; TELOMERE SHORTENING; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84888120047     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/18756921113119990004     Document Type: Article

References (68)

1. Kim HJ, Barsevick AM, Tulman L. Predictors of the intensity of symptoms in a cluster in patients with breast cancer. J Nurs Schol 2009; 41(2): 158-65.
2. Liu L, Fiorentino L, Natarajan L, et al. Pre-treatment symptom cluster in breast cancer patients is associated with worse sleep, fatigue and depression during chemotherapy. Psychooncology 2009; 18(2): 187-94.
3. Rietman J, Dijkstra P, Debreczeni R, et al. Impairments, disabilities and health related quality of life after treatment of breast cancer: A follow-up study 2.7 years after surgery. Disabil Rehabil 2004; 26(2): 78-84.
4. Kim E, Jahan T, Aouizerat BE, et al. Differences in symptom clusters identified using occurrence rates versus symptom severity rating in patients at the end of radiation therapy. Cancer Nurs 2009; 32(6): 429-36.
5. Dodd MJ, Cho MH, Cooper BA, Miaskowski C. The effect of symptom clusters on functional status and quality of life in women with breast cancer. Eur J Oncol Nurs 2010; 14(1): 101-10.
6. Montazeri A, Vahdaninia M, Harirchi I, et al. Quality of life in patients with breast cancer before and after diagnosis: An eighteen months follow-up study. BMC Cancer 2008; 8(11): 330-6.
7. Pud D, Ben Ami S, Cooper BA, et al. The symptom experience of oncology outpatients has a different impact on quality-of-life outcomes. J Pain Symptom Manag 2008; 35(2): 162-70.
8. Carlson LE, Campbell TS, Garland SN, et al. Associations among salivary cortisol, melatonin, catecholamines, sleep quality and stress in women with breast cancer and health controls. J Behavior Med 2007; 30(1): 45-58.
9. Payne JK, Held J, Thorpe J, et al. Effect of exercise on biomarkers, fatigue, sleep disturbances, and depressive symptoms in older women with breast cancer receiving hormonal therapy. Oncol Nurs Forum 2008; 35(4): 635-42.
10. Thornton LM, Andersen BL, Blakely WP. The pain, depression, and fatigue symptom cluster in advanced breast cancer: Covariation with the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. Health Psychol 2010; 29(3): 333-7.
11. Bower JE, Ganz PA, Aziz N, et al. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002; 64(4): 604-11.
12. Lyon DE, McCain NL, Walter J, et al. Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res 2008; 57(1): 51-8.
13. Seruga B, Zhang H, Bernstein LJ, et al. Cytokines and their relationship to the symptoms and outcome of cancer. Nature Rev Cancer 2008; 8: 887-99.
14. Lutgendorf SK, Sood AK. Biobehavioral factors and cancer progression: physiological pathways and mechanisms. Psychosom Med 2011; 73: 724-30.
15. Veeck J, Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplas 2008; 15(1): 5-17.
16. McCain NL, Gray DP, Walter JM, et al. Implementing a comprehensive approach to the study of health dynamics using the psychoneuroimmunology paradigm. Adv Nurs Sci 2005; 28(4): 320-32.
17. Wüst S, Federenko IS, Van Rossum EFC, et al. A psychobiological perspective on genetic determinants of hypothalamus-pituitaryadrenal axis activity. Ann NY Acad Sci 2004; 1032(1): 52-62.
18. Jabbi M, Korf J, Kema IP, et al. Convergent genetic modulation of the endocrine stress response involves polymorphic variations of 5HTT, COMT, and MAOA. Mol Psychiatry 2007; 12, 483-90.
19. Miller AH, Ancoli-Israel S, Bower JE, et al. Neuroendocrineimmune mechanisms of behavioral comorbities in patients with cancer. J Clin Oncol 2008; 26(6): 971-82.
20. Papadimitriou A, Priftis KN. Regulation of the hypothalamicpituitary-adrenal axis. Neuroimmunomodulation 2009; 16: 265-71
21. Mathews HL, Witek Janusek L. Epigenetics and psychoneuroimmunology: mechanisms and models. Brain Behav Immun 2011; 25(1): 25-39.
22. Kawai T, Morita K, Masuda K, et al. Gene expression signature in peripheral blood cells from medical students exposed to chronic psychological stress. Biol Psychol 2007; 76(3): 147-55.
23. Pyter LM, Pineros V, Galang JA, et al. Peripheral tumors induce depressive-like behaviors and cytokine production and alter hypothalamic-pituitary-adrenal axis regulation. Proc Nat Acad Sci USA 2009; 106: 9069-74.
24. Turan N, Katari S, Coutifaris C, et al. Explaining inter-individual variability in phenotype: is epigenetics up to the challenge? Epigenetics 2010; 5(1): 16-9.
25. Li L, Lou Z, Wang L. The role of FKBP5 in cancer aetiology and chemoresistance. Br J Cancer 2011; 104: 19-23.
26. Kang JI, Chung HC, Jeung H, et al. FKBP5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: A controlled and prospective study. Psychoneuroendocrin 2012; 37(9): 1569-76.
27. Klengel T, Mehta D, Anacker C, et al. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nature Neurosci 2012; 16; 33-41.
28. Lutgendorf SK, Costanzo ES. Psychoneuroimmunology and health psychology: an integrative model. Brain Behav Immun 2003; 17: 225-32.
29. Miller GE, Chen E, Sze J, et al. A functional genomic fingerprint of chronic stress in humans: Blunted glucocorticoid and increased NF-kappa B signaling. Biol Psychiatry 2008; 64(4): 266-72.
30. Sfikas A, Batsi C, Tselikou E, et al. The canonical NFkB pathway differentially protects normal and human tumor cells from ROS induced DNA damage. Cell Signal 2012; 24: 2007-23.
31. Bower JE, Ganz PA, Tao ML, et al. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin Cancer Res 2009; 15(17): 5534-40.
32. Schmidt MV, Sterlemann V, Müller MB. Chronic stress and individual vulnerability. Ann NY Acad Sci 2008; 1148(1): 174-83.
33. Hillhouse EW, Grammatopoulous DK. The molecular mechanisms underlying the regulation of the biological activity of corticotropinreleasing hormone receptors: implications for physiology and pathophysiology. Endocrinol Rev 2006; 27: 260-86.
34. Tyrka AR, Price LH, Gelernter J, et al. Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitary-adrenal axis reactivity. Biol Psychiatry 2009; 66(7): 681-5.
35. Heim C, Mletzko T, Purselle D, et al. The dexamethasone/ corticotropin-releasing factor test in men with major depression: role of childhood trauma. Biol Psychiatry 2008; 63(4): 398-405.
36. DeRijk RH. Single nucleotide polymorphisms related to HPA axis reactivity. Neuroimmunomod 2009; 16: 340-52.
37. Ressler KJ, Bradley B, Mercer KB, et al. Polymorphisms in CRHR1 and the serotonin transporter loci: gene x gene x environment interactions on depressive symptoms. Amer J Med Genet B Neuropsych Genet 2010; 153B(3): 812-24.
38. DeRijk RH, Wust S, Meijer OC, et al. A common polymorphism in the mineralcorticoid receptor modulates stress responsiveness. J Clin Endocrinol Metab 2006; 91: 5083-9.
39. Zobel A, Jessen F, von Widdern O, et al. Unipolar depression and hippocampal volume: impact of DNA sequence variants of the glucocorticoid receptor gene. Amer J Med Genet B Neuropsych Genet 2008; 147B: 836-43.
40. Mormede P, Foury A, Barat P, et al. Molecular genetics of hypothalamic-pituitary-adrenal axis activity and function. Ann NY Acad Sci 2011; 1220: 127-36.
41. Bower JE, Ganz PA, Aziz N. Altered cortisol response to psychological stress in breast cancer survivors with persistent fatigue. Psychosomatic Med 2005; 67: 277-80.
42. Payne J, Piper B, Rabinowitz I, et al. Biomarkers, fatigue, sleep and depressive symptoms in women with breast cancer: a pilot study. Oncol Nurs Forum 2006; 33(4): 775-83.
43. Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 1988; 12(2): 123-37.
44. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003; 97(11): 2919-25.
45. Dantzer R, Capuron L, Irwin MR, et al. Identification and treatment of symptoms associated with inflammation in medically ill patients. Psychoneuroendocrin 2008; 33(1): 18-29.
46. Dantzer R, O'Connor JC, Freund GG, et al. From inflammation to sickness and depression: When the immune system subjugates the brain. Nature Rev Neurosci 2008; 9(1): 46-56.
47. Wichers MC, Kenis G, Koek GH, et al. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. J Psychosomatic Res 2007; 62(2), 207-14.
48. Wichers MC, Maes M. Mechanisms of interferon-alpha-induced depressive symptoms. Acta Neuropsychiatrica 2002; 14(1): 103-5
49. Ahles TA, Saykin AJ, McDonald BC, et al. Cognitive function in breast cancer patient prior to adjuvant treatment. Breast Cancer Res Treat 2008; 110: 143-52.
50. Wefel JS, Lenzi R, Theriault R, et al. Chemobrain in breast carcinoma? A prologue. Cancer 2004; 101: 466-75.
51. Lyon DE, Walter J, Starkweather AR, et al. Tryptophan degradation in women with breast cancer: A pilot study. BMC Research Notes 2011; 4: 156-64.
52. Miaskowski C, Dodd M, Lee K, et al. Preliminary evidence of an association between a functional interleukin-6 polymorphism and fatigue and sleep disturbance in oncology patients and their family caregivers. J Pain Symptom Manag 2010; 40(4): 531-44.
53. Aouizerat BE, Dodd M, Lee K, et al. Preliminary evidence of a genetic association between tumor necrosis factor alpha and the severity of sleep disturbance and morning fatigue. Biol Res Nurs 2009; 11(1): 27-44.
54. Collado-Hidalgo A, Bower JE, Ganz PA, et al. Cytokine gene polymorphisms and fatigue in breast cancer survivors: Early findings. Brain Behav Immun 2008; 22(8): 1197-1200.
55. Bower JE, Ganz PA, Irwin MR, et al. Fatigue and gene expression in human leukocytes: increased NFB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain Behav Immun 2011; 25(1): 147-50.
56. Reyes-Gibby CC, Spitz MR, Yennurajalingam S, et al. Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer Epid Biomarkers Prev 2009; 18(10): 2636-42.
57. Reimann F, Cox JJ, Belfer I, et al. Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc Nat Acad Sci USA 2010; 107(11): 5148-53.
58. Dunn LB, Aouizerat BE, Langford DJ, et al. Cytokine gene variation is associated with depressive symptom trajectories in oncology patients and family caregivers. Eur J Oncol Nurs 2013; 17(3): 346-53.
59. Blackburn EH. Walking the walk from genes through telomere maintenance to cancer risk. Cancer Prevent Res 2011; 4(4): 473-5
60. Calado R, Young N. Telomeres in disease. F1000 Med Rep 2012; 4: 8.
61. Shammas MA. Telomeres, lifestyle, cancer and aging. Curr Opin Clin Nutr Metab Care 2010;14: 28-34.
62. Simon NM, Smoller JW, McNamara KL, et al. Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry 2006; 60: 432-435.
63. Wolkowitz OM, Mellon SH, Epel ES, et al. Leukocyte telomere length in major depression: Correlations with chronicity, inflammation and oxidative stress Preliminary findings. PLoS One 2011; 6(3): e1737.
64. Biegler KA, Anderson AKL, Wenzel LB, et al. Longitudinal change in telomere length and the chronic stress response in a randomized pilot biobehavioral clinical study: Implications for cancer prevention. Cancer Prev Res 2012; 5(10): 1173-82.
65. Brennan K, Garcia-Closas M, Orr N, et al. Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res 2012; 72(9): 2304-13.
66. Song L, Lin C, Wu Z, et al. miR-18a impairs DNA damage response through downregulatin of ataxia telangiectasia mutated (ATM) kinase. PLoS One 2011; 6(9): e25454.
67. van de Voorde L, Speeckaert R, van Gestel D, et al. DNA methylation-based biomarkers in serum of patients with breast cancer. Mutat Res 2012; 751: 304-25.
68. Heyn H, Carmona FJ, Gomez A, et al. DNA methylation profiling in breast cancer discordant identical twins identified DOK7 as novel epigenetic biomarker. Carcinogenesis 2012; 34(1): 102-8.